Log in

NASDAQ:VRTXVertex Pharmaceuticals Stock Price, Forecast & News

$284.82
-9.63 (-3.27 %)
(As of 07/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$283.85
Now: $284.82
$296.85
50-Day Range
$263.89
MA: $283.21
$299.06
52-Week Range
$165.23
Now: $284.82
$306.08
Volume1.67 million shs
Average Volume1.93 million shs
Market Capitalization$73.85 billion
P/E Ratio49.36
Dividend YieldN/A
Beta0.94
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; and Kymera Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Read More
Vertex Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VRTX
CUSIP92532F10
Phone617-341-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.16 billion
Cash Flow$4.61 per share
Book Value$23.66 per share

Profitability

Net Income$1.18 billion

Miscellaneous

Employees3,000
Market Cap$73.85 billion
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive VRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.

Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

How has Vertex Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Vertex Pharmaceuticals' stock was trading at $220.34 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VRTX shares have increased by 29.3% and is now trading at $284.82. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Vertex Pharmaceuticals?

29 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 8 hold ratings, 20 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vertex Pharmaceuticals.

When is Vertex Pharmaceuticals' next earnings date?

Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Vertex Pharmaceuticals.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its earnings results on Wednesday, April, 29th. The pharmaceutical company reported $2.56 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.84 by $0.72. The pharmaceutical company had revenue of $1.52 billion for the quarter, compared to the consensus estimate of $1.28 billion. Vertex Pharmaceuticals had a return on equity of 25.69% and a net margin of 31.35%. The business's revenue for the quarter was up 76.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.14 earnings per share. View Vertex Pharmaceuticals' earnings history.

How will Vertex Pharmaceuticals' stock buyback program work?

Vertex Pharmaceuticals announced that its board has authorized a stock repurchase program on Wednesday, July 31st 2019, which allows the company to buyback $500,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase up to 1.2% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's board of directors believes its shares are undervalued.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Wednesday, April, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $5.3-5.6 billion, compared to the consensus revenue estimate of $5.33 billion.

What price target have analysts set for VRTX?

29 brokers have issued 1 year target prices for Vertex Pharmaceuticals' stock. Their forecasts range from $220.00 to $330.00. On average, they anticipate Vertex Pharmaceuticals' share price to reach $285.12 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price. View analysts' price targets for Vertex Pharmaceuticals.

What are Wall Street analysts saying about Vertex Pharmaceuticals stock?

Here are some recent quotes from research analysts about Vertex Pharmaceuticals stock:
  • 1. Maxim Group analysts commented, "Vertex reported 2Q19 with cystic fibrosis (CF) revenue of $940M, beating consensus of $886.2M, up 25% y/y and 10% sequentially. All three approved CF drugs beat consensus; Kalydeco $262M vs. $254.5M, Orkambi $316M vs. $284.2M, and Symdeko $362M vs. $340.8M. Topline flowed through to the bottom line with $1.26 beating consensus of $1.07. Vertex ended the period with $4B in cash." (8/2/2019)
  • 2. HC Wainwright analysts commented, "Our price target of $220/share, is based on an equally weighted composite of: (a) $216/share, as a 30x multiple of taxed and diluted FY26 GAAP EPS of $22.94 discounted back to and (b) an NPV of $224/share (discount rate 11.0%, terminal growth rate of 2.0%). Risks to our investment thesis and target price include: (1) the failure of in further combination clinical studies; (2) the failure of to achieve our peak sales revenue; and (3) product competition." (8/1/2019)

Has Vertex Pharmaceuticals been receiving favorable news coverage?

Media coverage about VRTX stock has been trending very negative on Tuesday, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vertex Pharmaceuticals earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media stories about the pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Vertex Pharmaceuticals.

Who are some of Vertex Pharmaceuticals' key competitors?

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include Companhia de Saneamento Bsc DEDSP (SBS), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Paypal (PYPL), Micron Technology (MU), Gilead Sciences (GILD), Netflix (NFLX), Adobe (ADBE) and Skyworks Solutions (SWKS).

Who are Vertex Pharmaceuticals' key executives?

Vertex Pharmaceuticals' management team includes the following people:
  • Mr. Jeffrey Marc Leiden, Chairman, CEO & Pres (Age 63)
  • Mr. Michael J. Parini, Exec. VP and Chief Legal & Admin. Officer (Age 44)
  • Mr. Amit K. Sachdev, Exec. VP & Chief Regulatory Officer (Age 51)
  • Mr. Stuart A. Arbuckle, Exec. VP & Chief Commercial Officer (Age 53)
  • Dr. Jeffrey A. Chodakewitz, Sr. Advisor (Age 63)

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include MERIAN GLOBAL INVESTORS UK Ltd (0.07%), Envestnet Asset Management Inc. (0.06%), Cullinan Associates Inc. (0.04%), State of Alaska Department of Revenue (0.02%), Manning & Napier Group LLC (0.02%) and DNB Asset Management AS (0.01%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bruce I Sachs, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, Thomas Graney, William D Young and Yuchun Lee. View institutional ownership trends for Vertex Pharmaceuticals.

Which major investors are selling Vertex Pharmaceuticals stock?

VRTX stock was sold by a variety of institutional investors in the last quarter, including IFM Investors Pty Ltd, Gradient Investments LLC, Global Trust Asset Management LLC, Exane Derivatives, Municipal Employees Retirement System of Michigan, Nelson Van Denburg & Campbell Wealth Management Group LLC, and Alpha Windward LLC. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bruce I Sachs, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young, and Yuchun Lee. View insider buying and selling activity for Vertex Pharmaceuticals.

Which major investors are buying Vertex Pharmaceuticals stock?

VRTX stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., MERIAN GLOBAL INVESTORS UK Ltd, State of Alaska Department of Revenue, Chesley Taft & Associates LLC, Patton Fund Management Inc., Investment House LLC, DNB Asset Management AS, and Cypress Capital Group. View insider buying and selling activity for Vertex Pharmaceuticals.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $284.82.

How big of a company is Vertex Pharmaceuticals?

Vertex Pharmaceuticals has a market capitalization of $73.85 billion and generates $4.16 billion in revenue each year. The pharmaceutical company earns $1.18 billion in net income (profit) each year or $4.29 on an earnings per share basis. Vertex Pharmaceuticals employs 3,000 workers across the globe.

What is Vertex Pharmaceuticals' official website?

The official website for Vertex Pharmaceuticals is www.vrtx.com.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.